

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Directorate change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023.

Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme.

Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support the focus on driving each business unit and the Group to profitability.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Graham Lloyd Myers (aged 60):

Current Directorships	Previous Directorships held in the past five years
Croda Pension Trustees Limited	Bio Futures PI Limited
Croda Trustees Limited	Cargill Bioindustrial BV (Previously Croda Nederland BV)
	Cowick Insurance Services Limited
	Croda (Thailand) Co Ltd
	Croda Cosmetics & Toiletries Limited
	Croda Food Services Limited
	Croda India Company Private Limited
	Croda Investments Limited
	Croda Investments No 2 Limited
	Croda Investments No 3 Limited
	Croda Overseas Holdings Limited
	Croda Polymers International Limited
	Croda World Traders Limited
	Enza Biotech AB

	Lanxess Urethanes UK Ltd
	P. I. Bioscience Limited
	Plant Impact Limited
	PT. Croda Indonesia LLC
	Uniqema Limited
	Uniqema UK Limited

Graham Myers holds no ordinary shares, options or warrants over ordinary shares in the Company.

There is no further information regarding Graham Myers required to be disclosed under the AIM Rules.

Stephen OHara, CEO of OptiBiotix commented: *"We are pleased to confirm the appointment of Graham Myers as Finance Director. The appointment reflects the progress we have made in 2023 after a difficult 2022 and the Board's focus on controlling costs and building revenues to create a profitable international business with well-known global brands".*

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

Peterhouse Capital Limited (Joint Broker)
Duncan Vasey/ Lucy Williams

Tel: 020 7220 9797

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAEFLFBXLLEFBF